Biosite Expands Distributor Network in the Physician Office Segment
March 05 2007 - 8:00AM
PR Newswire (US)
SAN DIEGO, March 5 /PRNewswire-FirstCall/ -- Biosite Incorporated
(NASDAQ:BSTE) today announced the addition of McKesson Corporation
to its distributor network. McKesson joins Physician Sales and
Service (PSS), Henry Schein/Caligor and Fisher HealthCare Division
of Thermo Fisher Scientific Company as distributors of Biosite's
point-of-care diagnostic products to the physician office market.
"McKesson's knowledge and market leadership position in key states
expands our sales efforts in primary care," said Kim Blickenstaff,
Biosite's chairman and chief executive officer. "The addition of
McKesson to our physician office distribution network further
strengthens our commitment to the primary care market and will
allow us to provide more physicians with access to our product
portfolio." Biosite's leading product offering for physicians
treating outpatients is the Triage(R) BNP Test, which aids in the
diagnosis and assessment of heart failure and in the risk
stratification of patients with acute coronary syndromes and/or
heart failure. The CLIA-waived blood test can be entirely performed
in approximately 15-minute, using a small, portable meter. Biosite
offers a variety of other rapid tests for cardiovascular
conditions, drug screening and infectious diseases. For information
about how to order Biosite products, please contact Biosite at
(888) BIOSITE (246-7483), or email: . About Biosite Incorporated
Biosite Incorporated is a leading bio-medical company
commercializing proteomics discoveries for the advancement of
medical diagnosis. The Company's products contribute to
improvements in medical care by aiding physicians in the diagnosis
of critical diseases and health conditions. The Biosite(R)
Triage(R) rapid diagnostic tests are used in more than 50 percent
of U.S. hospitals and in more than 60 international markets.
Information on Biosite can be found at http://www.biosite.com/.
Except for the historical information presented herein, matters
discussed in this press release are forward-looking statements that
are subject to certain risks and uncertainties that could cause
actual results to differ materially from any future results,
performance or achievements expressed or implied by such
statements. Statements that are not historical facts, including but
not limited to statements that are preceded by, followed by, or
that include the words "will"; "believes"; "should"; "intends";
"anticipates"; "plans"; "expects"; "estimates"; or similar
statements are forward-looking statements. Forward looking
statements include statements concerning McKesson's ability to
expand our sales efforts in the primary care market and physician
access to our product portfolio. Risks and uncertainties include
risks associated with McKesson's ability to sell our products to
physician office laboratories, changing market conditions, the
availability of competitive products, and the extent to which our
products and products under development are successfully developed
and gain market acceptance. Other risks that should be considered
include, risks associated with the introduction of competitive
products from companies with greater capital and resources,
contract disputes, patent conflicts, product recalls, manufacturing
constraints, backlog, delays, or inefficiencies, shipment problems,
seasonal customer demand, the timing of significant orders, changes
in reimbursement policies, competitive pressures on average selling
prices, changes in the mix of products sold, and the other risks
detailed Biosite's most recent Annual Report on Form 10-K, and
subsequent SEC filings. The Company disclaims, however, any intent
or obligation to update these forward-looking statements. Copies of
Biosite's public disclosure filings are available from the investor
relations department. Biosite(R), Triage(R) and New Dimensions in
Diagnosis(R) are registered trademarks of Biosite Incorporated. The
Company's logo is a trademark of Biosite Incorporated. DATASOURCE:
Biosite Incorporated CONTACT: Nadine Padilla, Vice President,
Corporate & Investor Relations of Biosite Incorporated,
+1-858-805-2820, Web site: http://www.biosite.com/ Company News
On-Call: http://www.prnewswire.com/comp/116737.html
Copyright
Biosite (NASDAQ:BSTE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Biosite (NASDAQ:BSTE)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Biosite (MM) (NASDAQ): 0 recent articles
More Biosite (MM) News Articles